600062 Stock Overview
China Resources Double-Crane Pharmaceutical Co.,Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
China Resources Double-Crane Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.80 |
| 52 Week High | CN¥26.15 |
| 52 Week Low | CN¥15.94 |
| Beta | 0.17 |
| 11 Month Change | -13.62% |
| 3 Month Change | 6.34% |
| 1 Year Change | 12.07% |
| 33 Year Change | 66.13% |
| 5 Year Change | 68.01% |
| Change since IPO | 630.67% |
Recent News & Updates
The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 29
China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement
Oct 21An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued
Sep 30Recent updates
The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 29China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement
Oct 21An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued
Sep 30We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease
Jul 16China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 24Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel
Mar 02Shareholder Returns
| 600062 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.9% | -1.5% | -2.1% |
| 1Y | 12.1% | -9.4% | 2.8% |
Return vs Industry: 600062 exceeded the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 600062 exceeded the CN Market which returned 2.8% over the past year.
Price Volatility
| 600062 volatility | |
|---|---|
| 600062 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 600062 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600062's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 12,269 | Wenchao Lu | www.dcpc.com |
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, and other.
China Resources Double-Crane Pharmaceutical Co.,Ltd. Fundamentals Summary
| 600062 fundamental statistics | |
|---|---|
| Market cap | CN¥21.36b |
| Earnings (TTM) | CN¥1.35b |
| Revenue (TTM) | CN¥10.32b |
15.8x
P/E Ratio2.1x
P/S RatioIs 600062 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600062 income statement (TTM) | |
|---|---|
| Revenue | CN¥10.32b |
| Cost of Revenue | CN¥4.54b |
| Gross Profit | CN¥5.79b |
| Other Expenses | CN¥4.44b |
| Earnings | CN¥1.35b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.31 |
| Gross Margin | 56.06% |
| Net Profit Margin | 13.06% |
| Debt/Equity Ratio | 6.3% |
How did 600062 perform over the long term?
See historical performance and comparison